Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
तुलना करने के लिए मीट्रिक्स | DMRA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधDMRAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.3x | −4.6x | −0.4x | |
PEG अनुपात | 0.01 | −0.01 | 0.00 | |
क़ीमत/बुक | −8.7x | 2.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 2.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 77.0% | 178.7% | 46.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.4% | 7.6% | अनलॉक करें |